Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial.

Background: There is limited information about the use of antithrombotic therapies and outcomes of Latin American (LatAm) subjects with atrial fibrillation. The global ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48) trial compared the efficacy and safety of edoxaban versus warfarin over a median follow-up of 2.8 years.

Demonstration of a relation between urinary digoxin-like immunoreactive substance and cardiac performance.

Objective: To determine the relation between urinary digoxin-like immunoreactive substance (DLIS) and cardiac performance.

Design: Cohort study.

Setting: Echocardiography laboratory of a university-affiliated teaching hospital.